IDH1/2 mutations are also present in approximately 80% of grade II-III gliomas (Cohen, Holmen & Colman, 2013), producing a CpG island hypermethylator phenotype (Noushmehr et al., 2010). This evidence concerns the gene IDH1 and glioma.